Management of Chronic Systemic Immune-Mediated Reactions

Introduction to Management

• The American Academy of Allergy, Asthma, and Immunology recommends documenting reaction details, including time of onset, symptoms, and severity, when managing chronic systemic immune-mediated reactions to hyaluronidase 1
• The assessment of reaction severity should include grading the reaction from mild (Grade 1) to life-threatening (Grade 4) and evaluating for signs of anaphylaxis, which would require immediate epinephrine, as suggested by the Journal of Allergy and Clinical Immunology 2

Treatment Approach

• Antihistamines, such as second-generation H1 antihistamines, are recommended for symptom control, but should not replace corticosteroids in managing significant systemic reactions, according to the Journal of Allergy and Clinical Immunology 2
• Corticosteroids should be administered at a dose equivalent to 1-2 mg/kg of intravenous methylprednisolone every 6 hours until symptoms resolve, as recommended by the American Society of Clinical Oncology 3
• The initial dose of prednisone can be 20 mg daily for 2-4 weeks, or 1 mg/kg/day or equivalent, and should be continued for 2-4 weeks or until symptoms improve to grade 1, with a taper over 4-8 weeks or until grade 1 4
• Patients should be monitored for at least 30 minutes after initial treatment to ensure stabilization, as recommended by the Journal of Allergy and Clinical Immunology 5, 2

Monitoring and Follow-up

• The American College of Allergy, Asthma, and Immunology suggests scheduling follow-up visits every 1-2 weeks during the active treatment phase to monitor for resolution of symptoms, corticosteroid-related side effects, and signs of infection in immunocompromised patients 2, 5
• The American Academy of Allergy, Asthma, and Immunology advises monitoring for resolution of symptoms, including rash, joint pain and swelling, fever, and other systemic symptoms, and watching for steroid-related side effects, particularly in elderly patients 6, 7
• The following table summarizes the grading of delayed hypersensitivity reactions:

3

• Delayed hypersensitivity reactions should be assessed based on severity and treated accordingly, with a shorter course of corticosteroids (5-7 days) generally preferred for delayed reactions occurring 5-7 days after injection, as recommended by the American Society of Hematology 7

Special Considerations

• In patients with a history of heart failure or arrhythmia, the European Society of Cardiology suggests considering administering half the dose per day on two consecutive days and/or prolonging the administration of each infusion 6
• For immunocompromised patients, the Infectious Diseases Society of America recommends special care be given to the prevention and management of infections 6
• Consider prophylactic measures for osteoporosis if longer treatment is needed, as recommended by the American College of Rheumatology and the National Comprehensive Cancer Network 6, 7
• The American College of Rheumatology recommends identifying and discontinuing the triggering agent, which may include antibiotics, anticonvulsants, anti-inflammatory agents, vaccines, or supplements, to manage serum sickness-like reactions 6
• The American Society of Clinical Oncology recommends stopping administration of the triggering agent if an infusion is ongoing for managing injection site reactions 3

Prognosis and Recurrence

• Most patients respond well to treatment with complete resolution of symptoms, with a mean recovery time of approximately 6-8 days with appropriate treatment, according to the National Institute of Allergy and Infectious Diseases 6
• Recurrence is possible with re-exposure to the triggering agent, as noted by the Centers for Disease Control and Prevention 6